PPA
CUE icon

Parametric Portfolio Associates’s Cue Biopharma CUE Stock Holding History

Parametric Portfolio Associates’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$163K Sell
1,116
-148
-12% -$31.4K ﹤0.01% 3487
2021
Q4 		$429K Sell
1,264
-11
-0.9% -$4.25K ﹤0.01% 3125
2021
Q3 		$557K Buy
1,275
+370
+41% +$129K ﹤0.01% 3057
2021
Q2 		$316K Buy
905
+236
+35% +$91.5K ﹤0.01% 3253
2021
Q1 		$245K Buy
669
+135
+25% +$55.6K ﹤0.01% 3797
2020
Q4 		$200K Buy
534
+24
+5% +$9.59K ﹤0.01% 3777
2020
Q3 		$230K Sell
510
-57
-10% -$32.8K ﹤0.01% 3598
2020
Q2 		$417K Buy
567
+182
+47% +$132K ﹤0.01% 3348
2020
Q1 		$164K Buy
+385
New +$187K ﹤0.01% 3604
2019
Q4 		– Sell
-336
Closed -$85K – 3968
2019
Q3 		$85K Buy
+336
New +$80.7K ﹤0.01% 3853

Other funds holding CUE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's CUE Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Cue Biopharma (CUE) stake by 12% in Q1 2022, selling an estimated $31.4K and leaving 1,116 shares worth $163K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Parametric Portfolio Associates first reported a position in CUE in Q3 2019 and has held it in 10 quarters since. The position peaked at $557K in Q3 2021. 100 funds tracked by Wall St. Rank hold CUE as of Q1 2022.

  • Parametric Portfolio Associates held 1,116 shares of Cue Biopharma worth $163K as of Q1 2022.
  • Parametric Portfolio Associates sold 148 Cue Biopharma shares in Q1 2022, an estimated $31.4K.
  • Cue Biopharma made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3487 holding.
  • Parametric Portfolio Associates first reported a position in Cue Biopharma in Q3 2019 and has held it in 10 quarters since.
  • Parametric Portfolio Associates's Cue Biopharma position peaked at $557K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.